市場調査レポート

世界における医薬品受託製造市場

Pharmaceutical Contract Manufacturing

発行 Global Industry Analysts, Inc. 商品コード 236772
出版日 ページ情報 英文 185 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
世界における医薬品受託製造市場 Pharmaceutical Contract Manufacturing
出版日: 2014年06月01日 ページ情報: 英文 185 Pages
概要

当レポートでは、世界の医薬品受託製造市場について分析し、米国、カナダ、日本、欧州、アジア太平洋地域、中東、ラテンアメリカなどの地域別の動向、今後の市場予測、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 幕開け
    • 費用とリスクの封じ込め策が生物医薬品生産のアウトソーシングを促進
    • 主な市場牽引因子
    • 不況による停滞から生物医薬品受託製造市場が台頭
    • 医薬品業界における好ましい動向が医薬品受託製造市場に明るい見通しをもたらす
    • 世界的人口増加が成長の機会を増大
    • ジェネリック医薬品の増加が医薬品受託製造業者にメリット
    • 欧米市場が独占するもアジア太平洋市場が成長の勢い
    • 大きな変化が将来の明るい見通しに
    • 固形製剤が医薬品受託製造業者に人気
    • 注射型製剤が市場の成長を拡大
  • 主な市場動向と課題
  • 他競合環境
    • 非常に細分化された業界による統合
    • 激しい競争とコモディティ化
    • 大企業が小規模企業を押しのける
    • 統合を促進する競争の激しい薬価設定
    • 注射剤市場における競争激化と能力およびサービスの拡大
  • サービス概要
    • 概要
    • 注射剤
    • 固形製剤
    • 液状製剤
    • 医薬品受託製造の台頭に対する考察
    • 投資リスク
    • 品質保証リスク
    • 薬剤開発リスク
    • 買収リスク
    • クライアント依存リスク
  • 近年の業界活動
  • 主要参入企業
    • AAIPharma Services Corporation
    • Aenova Group (Germany)
    • Haupt Pharma AG (Germany)
    • Ajinomoto Althea, Inc.
    • Albany Molecular Research Inc.
    • Boehringer Ingelheim GmbH
    • Catalent Pharma Solutions, Inc.
    • Dishman
    • DPx Holdings B.V.
    • Famar Health Care Services
    • Hospira, Inc.
    • Jubilant Life Sciences Limited
    • Kemwell Biopharma Pvt. Ltd
    • Lonza Group Ltd.
    • NextPharma Technologies Holding Ltd
    • ニプロファーマ株式会社
    • Recipharm AB
    • Cobra Biologics Holding AB
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
  • その他の諸国

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-1535

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 92 companies including many key and niche players such as -

AAIPharma Services Corporation
Aenova Group
Ajinomoto Althea, Inc.
Albany Molecular Research, Inc.
Dishman

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • A Curtain Raiser
  • Cost and Risk Containment Objectives Spur Outsourcing of Biopharma Production
  • Key Market Drivers
  • Biopharma Contract Manufacturing Market Emerges from the Recessionary Lull
    • Table 1: Worldwide Funding for Biotech Projects by Geographic Region (2012): Percentage Breakdown of Funding for North America, Europe, and Rest of World (includes corresponding Graph/Chart)
    • Table 2: Worldwide Funding for Biotech Projects by Product Development Phase (2012): Percentage Breakdown of Funding for Products in Clinical Trial, Pre-Clinical Trial and Commercialization Phases (includes corresponding Graph/Chart)
  • Favorable Trends in the Pharma Industry Portend Bright Outlook for the PCM Market
  • Ballooning Global Population Offers Increased Growth Opportunities
    • Table 3: Top 25 Countries Worldwide in Terms of Population: 2007, 2010 & 2013
  • Surge in Generic Drugs to Benefit Pharmaceutical Contract Manufacturers
    • Table 4: Worldwide Annual Spending on Drugs by Category (2011 & 2015): Percentage Breakdown of Dollar Sales for Branded Drugs, Generic Drugs, and Others (includes corresponding Graph/Chart)
    • Increasing Consumption Drugs within Aging Population Boosts Opportunities for PCM
    • Table 5: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 6: Elderly Population (65+ Years) as a % of Total Population (2025) (includes corresponding Graph/Chart)
    • Changing Healthcare Expenditure Trends to Spur Demand for Contract Manufacturing of Generics
    • Table 7: Healthcare Spending as a Percentage of GDP: 2012 (includes corresponding Graph/Chart)
  • US and Europe Dominate Market, Asia-Pacific Lends Growth Momentum
  • Major Changes Imperative to Capitalize on Brighter Future Prospects
  • Solid Dosage Form Retains Popularity among Pharma Contract Manufacturers
  • Injectable-Dose Formulations to Spearhead Growth of the PCM Market

2. MAJOR MARKET TRENDS & ISSUES

  • Patent Expiries Augur Good Tidings for the PCM Market
  • PCMs Gear Up to Tap Booming Biologics Market
  • PCM Market for Vaccines Yet to Take Off
  • Biotechnology Upstarts Spur Demand for Contract Manufacturing
  • Vendor Switching- A Growing Concern for PCMs
  • Marked Decrease Witnessed in Venture Capital Investment into PCM Upstarts
  • PCM Industry Gravitates Eastward, and Subsequently Leads to Near-Shoring
  • Adoption of Cutting-Edge Technologies to Radicalize PCM Environment
  • RABS technology
  • Quality by Design
  • Track & Trace Techniques
  • Disposable Processing Techniques
  • Upstream & Downstream Processes
  • Process Analytical Technology
  • Near Infrared Spectroscopy
  • Increased Regulator Scrutiny: A Cause of Concern for the Emerging Market PCMs

3. COMPETITIVE LANDSCAPE

  • PCM - A Highly Fragmented Industry Undergoing Consolidation
    • Table 8: Worldwide Pharmaceutical Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Catalent Pharma Solutions, DPx Holdings B.V., Famar Health Care Services, and Others (includes corresponding Graph/Chart)
    • Table 9: Worldwide Injectables Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Baxter, Hospira, Vetter and Others (includes corresponding Graph/Chart)
  • PCMs Battle Fierce Competition and Commoditization
  • Large Enterprises Edging Out Small-scale Players
  • Competitive Pricing Pressure to Spur Consolidation
  • Competition Heats Up in Injectables Market, PCMs Expand Capabilities and Service Offerings

4. SERVICE OVERVIEW

  • Introduction
  • Injectables (Injections, Vials, and IV solutions)
  • Solid Dosage Forms (SDFs) (Tablets and Capsules)
  • Liquid Dosage Forms (LDFs) (Syrups and Suspensions)
  • An Insight into the Rise of Pharmaceutical Contract Manufacturing
  • Investment Risks in Pharmaceutical Contract Manufacturing
  • Quality Assurance Risk
  • Drug Development Risk
  • Acquisition Risk
  • Client Dependency Risk

5. RECENT INDUSTRY ACTIVITY

  • Onyx Announces completion of API project with Neuronascent
  • Meiji Holdings Buys Medreich Lifecare Limited
  • Emilia Group Takes Over Pharma Pac LLC
  • AMRI to Take Over Cedarburg Pharma
  • AMRI to Acquire OsoBio Biopharmaceuticals Manufacturing
  • Royal DSM's DPP Merges with JLL Partners' Pantheon, Giving Rise to DPx Holdings B.V.
  • Emergent BioSolutions Takes Over Cangene Corporation
  • Dendreon Appoints PharmaCell as European CMO
  • Ajinomoto Acquires Althea Technologies
  • Aenova Group Merges with Haupt Pharma
  • Kemwell Biopharma Takes Over Cirrus Pharmaceuticals
  • Questcor Acquires BioVectra
  • ICON Buys Cross Country Healthcare's Clinical Trial Services Division
  • Columbia Laboratories Acquires Molecular Profiles
  • EPS Corp Acquires Gleneagles CRC from IHH Healthcare
  • Capsugel to Take Over Bend Research
  • Gallus BioPharmaceutical Takes Over Laureate Biopharmaceutical
  • PLI Holdings Acquires Pfanstiehl Laboratories
  • DPT Laboratories Announce Integration With Confab
  • Nordion Inks Contract Manufacturing Agreement with Navidea
  • Unilife Receives Injectables Contract from Hikma
  • NextPharma Technologies Expands Bielefeld Production Capacity and Capabilities
  • Fuji Pharma to Acquire OLIC from DKSH
  • DSM Pharmaceutical Partners Almac Group
  • Metrics Inc Introduces Generic Drug of Oxycodone HCl 5mg
  • Patheon Completes Acquires Banner Pharmacaps
  • PAREXEL International Acquires Liquent
  • American Capital Acquires Cambridge Major
  • Aenova Group Takes Over Euro Vital Pharma
  • Althea Technologies Receives Contract from Pfenex

6. FOCUS ON SELECT GLOBAL PLAYERS

  • AAIPharma Services Corporation (US)
  • Aenova Group (Germany)
  • Haupt Pharma AG (Germany)
  • Ajinomoto Althea, Inc. (US)
  • Albany Molecular Research Inc. (US)
  • Boehringer Ingelheim GmbH (Germany)
  • Catalent Pharma Solutions, Inc. (US)
  • Dishman (India)
  • DPx Holdings B.V. (US)
  • Famar Health Care Services (Greece)
  • Hospira, Inc. (US)
  • Jubilant Life Sciences Limited (India)
  • Kemwell Biopharma Pvt. Ltd (India)
  • Lonza Group Ltd. (Switzerland)
  • NextPharma Technologies Holding Ltd (UK)
  • Nipro Pharma Corporation (Japan)
  • Recipharm AB (Sweden)
  • Cobra Biologics Holding AB (Sweden)

7. GLOBAL MARKET PERSPECTIVE

    • Table 10: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 12: World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 13: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 15: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 18: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 21: World 15-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • US PCM Market Overview
    • Competitive Landscape
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 22: The US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 23: The US Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 24: The US 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 25: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 26: Canadian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 27: Canadian 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Strategic Corporate Development
    • Nipro Pharma Corporation - A Key Japanese Player
  • B. Market Analytics
    • Table 28: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 29: Japanese Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 30: Japanese 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • European PCM Market Caught in Eurodebt Doldrums
    • Injectables Segment Offers Promising Potential
    • Mammalian Cell Technology Dominates PCM Market
    • Competitive Scenario
    • Overview of Select Markets
      • Germany
      • Russia
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 31: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 32: European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 33: European 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Favorable Government Policies Transform China and India into PCM Hubs
    • Competitive Scenario
    • Overview of Select Regional Markets
      • China
      • Outsourcing Industry Bogged Down by Recession
      • India
      • Indian PCMs Battle Soaring Costs
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 34: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 35: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 36: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • Market Analysis
    • Table 37: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 38: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 39: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Back to Top